Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23747770 | 0.88 | RAB9A (0.55) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL26099203 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL26547254 | 0.81 | EPHX2 (0.71) | SMN1; SMN2MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL23747726 | 0.80 | MEN1 (0.54) | SMN1; SMN2MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL17916794 | 0.79 | SMN1; SMN2 (0.88) | SMN1; SMN2MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL26101183 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL23747557 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL23727610 | 0.78 | MEN1 (0.74) | SMN1; SMN2MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL26097972 | 0.78 | NPC1 (0.80) | SMN1; SMN2MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL23747392 | 0.77 | SMN1; SMN2 (0.75) | SMN1; SMN2MEN1KMT2AL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | SMN1; SMN2 1161/4885MEN1 484/4885KMT2A 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.